t-butyl N-acetyl-(L)-cysteinate | 178432-67-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: t-butyl N-acetyl-(L)-cysteinate
• 英文别名: tert-butyl N-acetylcysteinate；tert-butyl (2R)-2-acetamido-3-sulfanylpropanoate
• CAS: 178432-67-2
• 化学式: C₉H₁₇NO₃S
• 分子量: 219.305
• InChiKey: NCJOYSQUBVVKJB-ZETCQYMHSA-N

物化性质

• 沸点：
  348.6±32.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  56.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  C₇⁽¹³⁾C₄H₂₆ClNOSi 、 t-butyl N-acetyl-(L)-cysteinate 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以97%的产率得到tert-butyl (2R)-2-acetamido-3-[2-[2-[tert-butyl(dimethyl)silyl]oxy(1,2-13C2)ethyl-methylamino](1,2-13C2)ethylsulfanyl]propanoate
  参考文献：
  名称：

  Synthesis of 13C labeled sulfur and nitrogen mustard metabolites as mass spectrometry standards for monitoring and detecting chemical warfare agents

  摘要：

  采用易于获得且含13C标记的商业起始原料制备了含氮及含硫化学战剂代谢物的（>M+4）13C标记代谢物，这些新化学路线具有反应步骤少的效率优势，可以放大至克级规模，且以13C标记为基准的得率良好。这些标记化合物可用作监测化学战剂及其代谢物的质谱分析内标。2012年发表。本文为美国政府作品，在美国属于公有领域。

  DOI：

  10.1002/jlcr.2929
• 作为产物：
  描述：

  di-tert-butyl N-acetylcystinate 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 以90%的产率得到t-butyl N-acetyl-(L)-cysteinate
  参考文献：
  名称：

  丙烯酰胺和丙烯腈 D 标记氧化代谢物的合成，用于量化它们对人体的毒性

  摘要：

  丙烯酰胺和丙烯腈的标记氧化代谢物（用于评估人类接触重要毒物的参考化合物）的合成报告。为此，L-胱氨酸叔丁酯被乙酰化，产物还原裂解为 L-半胱氨酸叔丁酯，后者与氨基甲酰基 [D3] 环氧乙烷（从 [D3] 丙烯腈和 30% H2O2 水溶液中获得，pH = 7.0–7.5) 并提供 N-乙酰基-S-(2-羟基-2-氨基甲酰基[D3]乙基)半胱氨酸叔丁酯和 N-乙酰基-S-(1-氨基甲酰基-2-)叔丁酯的可分离混合物羟基[D3]乙基）半胱氨酸（约 9:1）。用水溶液去除这些中间体中的叔丁基。HCl 得到含有氨基甲酰基残留物的最终氘代内标物。在 DMF 中用 tBuMe2SiCl/咪唑保护主要中间体中的仲羟基，然后氨基甲酰基脱水（CH2Cl2 中的三氟乙酸酐/吡啶）并逐步去除叔丁基和 tBuMe2Si 保护基团（TFA、Et3SiH、CH2Cl2； aq. HF in MeCN) 产生 N-乙酰

  DOI：

  10.1002/ejoc.200800291

文献信息

• Combination Therapies for Treating Metabolic Disorders
  申请人：Mayoux Eric

  公开号：US20100239552A1

  公开（公告）日：2010-09-23

  This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.

  本发明涉及包含抗氧化剂、抗炎剂和可选地至少一种其他抗糖尿病药物的药物组合，用于治疗代谢紊乱。本发明还包括包含抗氧化剂、抗炎剂、可选地至少一种其他抗糖尿病药物和至少一种药用载体的药用可接受的组合物。本发明的这些组合和组合物作为治疗代谢紊乱的方法是有用的，包括糖尿病，特别是I型和II型糖尿病，以及与糖尿病相关的疾病和紊乱，包括但不限于动脉粥样硬化、心血管疾病、炎症性疾病、肾病、神经病、视网膜病变、β细胞功能障碍、血脂异常、LADA、代谢综合征、高血糖、胰岛素抵抗和/或慢性阻塞性肺疾病在哺乳动物，特别是糖尿病哺乳动物，特别是人类患者中。本发明特别涉及包含硫辛酸、来自二氟尼索、双氯芬酸、右布洛芬、右侧氧布洛芬、萘普生和水杨酸的一种或多种抗炎药物以及可选地一种或多种药用可接受的载体的药物组合。本发明的组合物作为治疗代谢紊乱的方法是有用的，包括II型糖尿病、胰岛素抵抗、β细胞功能障碍和高血糖在患者，特别是糖尿病患者中。
• A unique and highly facile method for synthesising disulfide linked neoglycoconjugates: a new approach for remodelling of peptides and proteins
  作者：Wallace M. Macindoe、Anita H. van Oijen、Geert-Jan Boons

  DOI：10.1039/a708701b

  日期：——

  An asymmetric disulfide linkage, formed by conjugation of a 5-nitropyridine-2-sulfenyl activated thioglycoside and a protein or pre-assembled peptide sequence, represents a good structural mimic of natural asparagine glycosylation.

  由 5-硝基吡啶-2-亚磺酰基活化硫代糖苷与蛋白质或预组装肽序列共轭形成的不对称二硫键是天然天冬酰胺糖基化的良好结构模拟物。
• COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS
  申请人：Genmedica Therapeutics SL

  公开号：EP2408441A1

  公开（公告）日：2012-01-25
• Combination Therapies For Treating Metabolic Disorders
  申请人：Genmedica Therapeutics SL

  公开号：US20140357602A1

  公开（公告）日：2014-12-04

  This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.
• [EN] COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS<br/>[FR] THÉRAPIES COMBINATOIRES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：GENMEDICA THERAPEUTICS SL

  公开号：WO2010106083A1

  公开（公告）日：2010-09-23

  This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable earner. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.